Management of Elevated DHEA-S Levels

Diagnostic Considerations

A DHEA-S level of 311 μg/dL (3110 ng/mL) in a woman requires urgent evaluation for adrenocortical carcinoma with immediate adrenal CT imaging, as this level is significantly elevated and approaches the threshold that strongly suggests malignancy 1
The American College of Endocrinology recommends evaluating patients with DHEAS >6000 ng/ml urgently for adrenal carcinomas, and while a patient with a level of 3110 ng/mL is below this threshold, the level is still markedly elevated and warrants immediate investigation 1
Rapidly progressive virilization symptoms (voice deepening, male-pattern baldness, clitoromegaly, increased muscle mass) strongly suggest malignancy and should not be delayed 1
Menstrual irregularity (oligomenorrhea or amenorrhea) is common with androgen-secreting tumors 1
Hirsutism with male escutcheon pattern is a significant finding 2
Timeline of symptom onset - rapid progression over weeks to months favors malignancy over benign conditions 1

Order the following tests on the same morning blood draw: androstenedione (rule out adrenal/ovarian tumor if >10.0 nmol/L) 2, LH and FSH (calculate LH/FSH ratio) 2, 17-hydroxyprogesterone (screen for non-classical congenital adrenal hyperplasia) 1, morning ACTH and cortisol (distinguish adrenal from pituitary sources) 1
Obtain adrenal CT scan with contrast immediately - do not wait for hormone results if clinical virilization is present 1
Look for tumor size >4-5 cm (highly suspicious for malignancy) 1, irregular margins or heterogeneous appearance 1, lipid-poor lesions that fail to wash out on contrast-enhanced CT 1, and multiple hormone secretion 1
Obtain transvaginal ultrasound to assess for polycystic ovaries (>10 peripheral cysts, 2-8 mm diameter) and ovarian masses 2, 1

Most likely diagnoses in order of concern for a DHEA-S level of 3110 ng/mL: adrenocortical carcinoma - approximately 60% present with virilization symptoms; peak incidence in fourth to fifth decades with female-to-male ratio of 1.5:1 1
Non-classical congenital adrenal hyperplasia - must be ruled out with 17-hydroxyprogesterone and 21-hydroxylase antibodies 1
Polycystic ovary syndrome (PCOS) - affects 4-6% of women in general population; characterized by LH/FSH ratio >2, testosterone >2.5 nmol/L, and polycystic ovaries on ultrasound 2
Benign adrenal adenoma - less likely with this degree of elevation but possible 1

Unilateral adrenalectomy is recommended for adrenal masses causing androgen excess, with minimally-invasive surgery when feasible 3
If malignancy is suspected (size >4-5 cm, irregular margins, heterogeneous), open adrenalectomy is preferred as these tumors are prone to rupture 4
For PCOS, assess for metabolic complications: fasting glucose/insulin ratio (ratio >4 suggests reduced insulin sensitivity), BMI, waist/hip ratio 2
Address menstrual irregularity and metabolic dysfunction in PCOS patients 2
Refer to endocrinology for glucocorticoid management if non-classical CAH is confirmed 1